[Adjuvant chemotherapy in premenopausal and menopausal high-risk patients with breast cancer. 4. Results of the DBCG (Danish Breast Cancer Cooperative Group) 77B study].
From October 1977 to November 1982 premenopausal and menopausal high-risk breast cancer patients were included in a randomized trial (DBCG 77B). The primary surgical treatment was total mastectomy with axillary dissection. In the trial, a total of 1,034 patients were enrolled and received postoperative radiotherapy (RT) and were further randomized to 1) no systemic treatment, 2) cyclophosphamide, or 3) cyclophosphamide + methotrexate + 5-fluorouracil. The chemotherapy was given for one year. With a median observation time of ten years, the survival was 45, 60 and 62%, respectively. Retrospectively, the survival benefit was observed to be most pronounced in the age group less than 40 years, in patients with tumour size less than or equal to 5 cm or with less than or equal to 3 positive lymph nodes. In high-risk premenopausal and menopausal patients adjuvant chemotherapy combined with RT thus resulted in a more than 25% relative reduction in mortality at ten years of observation compared with RT alone.
Dombernowsky
P
P
Finseninstitutet, Rigshospitalet, København.
Andersen
J A
JA
Andersen
K W
KW
Axelsson
C K
CK
Blichert-Toft
M
M
Hansen
M
M
Krag
C
C
Mouridsen
H T
HT
Overgaard
M
M
Rasmussen
B B
BB
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003718:Denmark; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors
D000970:Antineoplastic Agents
Adjuverende kemoterapi af praemenopausale og menopausale højrisikopatienter med cancer mammae. 4. Resultater fra DBCG 77B undersøgelsen.